O2matic PRO 100
How does it work
PRO 100 is an oxygen robot that optimizes oxygen treatment by regulating the oxygen supply based on a continuous measurement of the blood oxygen content. O2matic PRO 100 performs individually tailored monitoring and regulation of oxygen dosage using an advanced algorithm and input from a pulse oximeter.
A giant leap for oxygen treatment
A sensor (pulse oximeter) measures the patient’s blood oxygen level, and PRO 100’s advanced software automatically adjusts the dose of oxygen accordingly. At the same time, the PRO 100 monitors the patient’s vital parameters, pulse and SpO2, and gives an alarm if their condition requires attention.
Advantages of automatic oxygen treatment
- Reduces the time in hyperoxia by 56% and the time in severe hypoxemia (SpO2 < 85%) by 93%.
Significantly better at keeping patients in the correct oxygen range than the manual treatment.
- Increasing walking distance by 98% and halved shortness of breath in patients with severe COPD on the Borg scale from 8 to 4 (12).
- Close and continuous monitoring of oxygen treatment.
Alarm function that notifies of changes in the patient’s condition.
Shorter hospital stays and faster weaning offer clinical and health-economic benefits.
O2matic PRO 100 is an IIB-classed medical device and is CE marked by TÜV SÜD.
O2matic ApS is ISO13485 certified.
Read our latest white paper
Get our latest white paper about automatic oxygen therapy and the studies behind it sent to you by filling in the following:
In 2023s study, “Automated Oxygen Administration Alleviates Dyspnea in Patients Admitted with Acute Exacerbation of COPD,” researchers explored the impact of Automated Oxygen Administration (AOA) compared to traditional oxygen therapy for patients with acute exacerbation of COPD. Conducted in multiple centers across Denmark, the study included 157 patients who were randomly assigned to either AOA with the O2matic PRO or conventional nurse-administered oxygen therapy. The results revealed that AOA significantly reduces the intensity of dyspnea and improves oxygen saturation levels in patients with acute exacerbation of COPD.
In a qualitative study researchers delved into patients’ experiences with O2matic PRO during their hospitalization for COPD exacerbation. This study from 2023 studied the human side of AOA, aiming to uncover how patients perceive and interact with O2matic PRO. This study, which included 18 patients, unveils how O2matic PRO reduces breathing discomfort and physical perception of dyspnea in patients admitted with exacerbation of COPD.
A rehabilitation study with O2matic PRO 100 was published in October 2021
in the Journal of Clinical Medicine and showed an increased endurance when using O2matic PRO 100 during rehabilitation of Chronic Hypoxemic Patients.
In this study, the researchers found an increase of 98% in the time used walking before fatigue. Without automatic titrated oxygen, the patients could walk 5.5 minutes, and with our technology the patients saw an increase in walking ability to 10.9 minutes in average. Our webinar called Why oxygen robots could be a game changer” goes into depth on this topic.
O2matic PRO Reduces breathing discomfort and dyspnea in patients with acute exacerbation according to a multicenter randomized control study that was published in International Journal of Chronic Obstructive Pulmonary Disease. Alleviating dyspnea by O2matic PRO may therefore not only impact the patients’ quality of life, the length of hospital stays, and nurse resources, but can also be a potential palliative intervention across different etiologies.
|SpO2 above target
|SpO2 within target
|SpO2 below target, above 85%
|SpO2 lower than 85%
In December 2018, the first clinical results with the O2matic PRO 100 were published in the International Journal of COPD. The study included 20 patients admitted with COPD in a crossover trial . The results of the study show the difference between manually titrated oxygen by nursing staff and automatic oxygen titration with PRO 100. During manual titration, patients maintained the desired oxygen saturation for 47% of the time against 85% of the time with treatment with automatic oxygen titration. At the same time, the study shows that PRO 100 reduced the time in hyperoxia by 56% and the time in severe hypoxemia (SpO2 < 85%) by 93% .
In October 2020 during COVID, another clinical study was published with the O2matic PRO 100. This study deals with the treatment of patients with COVID-19 and shows the same clear improvement as the first study. The study is published in the European Clinical Respiratory Journal and showed that patients maintained an acceptable oxygen saturation for 94% of the time.
Sign up for our white paper here for more info on studies.